- Trial phase
- Preclinical / Early-stage
- Time to market
- At least 5-7 years, if ever; VLR247 is preclinical/early-stage with no registered clinical trials found.
- Why 3/10
- No hard dated catalyst is scheduled for VLR247 in the next ~12 months; the drug is preclinical/early-stage and was acquired via the Velaris reverse merger closed October 13, 2026, with proof-of-concept data for the lead PAH candidate VLR199 expected in 2028, not VLR247.
VLR247 is an early-stage ActRII-Fc fusion protein candidate for pulmonary arterial hypertension (PAH) that came to TCRT via the October 2026 reverse merger with Velaris Therapeutics. The stock's next major catalyst is proof-of-concept data for the lead PAH candidate VLR199 in 2028, not VLR247 specifically. Massive dilution (pro forma shares ~358 million vs ~4.2 million pre-merger) and a recently filed S-3 shelf registration for ~382 million shares for resale are overhangs.
Price Chart
Executive Summary
VLR247 is a preclinical ActRII-Fc fusion protein for pulmonary arterial hypertension (PAH) that Alaunos Therapeutics (TCRT) acquired through its October 2026 reverse merger with Velaris Therapeutics. The drug is designed to improve on first-generation ActRII-Fc therapies by sparing BMP-9 and BMP-10 to reduce hematologic side effects. It is at a very early stage with no clinical trials registered, and the company's near-term focus is on its lead PAH candidate VLR199, with proof-of-concept data expected in 2028. The reverse merger massively diluted existing TCRT shareholders (pro forma shares ~358 million vs ~4.2 million pre-merger), and a November 2026 S-3 shelf registration for ~382 million shares for resale adds further overhang.
How It Works
VLR247 is an engineered protein (an ActRII-Fc fusion) that blocks certain signaling molecules (activins) involved in the abnormal blood-vessel remodeling that drives pulmonary arterial hypertension. It is designed to avoid blocking BMP-9 and BMP-10, two related signals that are important for blood-vessel health, which could reduce side effects seen with earlier drugs in this class.
Trial Status
No active clinical trials found on ClinicalTrials.gov or in SecBot's pipeline database. VLR247 is described as an ActRII-Fc fusion protein designed to spare BMP-9 and BMP-10 to lower hematologic adverse event risk, targeting pulmonary arterial hypertension.
The Two-Sided Case
Upcoming Catalysts
- Proof-of-concept data for lead PAH candidate VLR199 expected in 2028 (not VLR247).
- No near-term catalysts for VLR247 itself are scheduled.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Alaunos Therapeutics, Inc. S-3 TCRT ·Originating report